ProQR has inked a deal with French company Laboratoires Théa and transferring two late-stage candidates to the company in a deal worth up to €147.5 million, or about $162 million.
The companies made the joint announcement Tuesday that Théa gets its hands on two single-strand oligonucleotide candidates, sepofarsen and ultevursen — paying €12.5 million, or roughly $13.7 million up front. ProQR noted the company is eligible for another €135 million, approximately $148 million, from Théa in more development, regulatory and commercial payments, plus royalties.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters